SELLAS Life Sciences Group (NASDAQ:SLS) Sets New 12-Month High – Time to Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s stock price hit a new 52-week high during trading on Wednesday . The company traded as high as $8.28 and last traded at $8.9910, with a volume of 376791 shares changing hands. The stock had previously closed at $7.59.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SLS. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Maxim Group upped their target price on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, SELLAS Life Sciences Group has an average rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Trading Down 15.7%

The firm’s fifty day moving average price is $5.23 and its 200-day moving average price is $3.91. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -32.87 and a beta of 2.24.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Trading of SELLAS Life Sciences Group

A number of large investors have recently bought and sold shares of SLS. Axxcess Wealth Management LLC acquired a new stake in SELLAS Life Sciences Group during the 3rd quarter worth $26,000. Larson Financial Group LLC acquired a new stake in SELLAS Life Sciences Group during the 4th quarter worth $26,000. BNP Paribas Financial Markets boosted its stake in SELLAS Life Sciences Group by 89.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after purchasing an additional 9,299 shares during the period. Concurrent Investment Advisors LLC acquired a new stake in SELLAS Life Sciences Group during the 4th quarter worth $38,000. Finally, Beacon Pointe Advisors LLC acquired a new stake in SELLAS Life Sciences Group during the 4th quarter worth $38,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.